Brain: Tumours
The question
To ask the Secretary of State for Health and Social Care, what discussions he has had with representatives of the pharmaceutical industry on access to clinical trials for brain tumour patients.
Answered by Andrew Gwynne
The Department is committed to working with the pharmaceutical industry to implement the recommendations of Lord O'Shaughnessy’s review into commercial clinical trials, maximising our potential to be a world leader in clinical trials.
The current programme governance groups overseeing the delivery on the recommendations of Lord O'Shaughnessy’s review, including improving access to clinical trials across the United Kingdom, includes representatives from the pharmaceutical industry and across the clinical research sector.
Through this programme, the Department is committed to working with the pharmaceutical industry to develop a more efficient, more competitive, and more accessible clinical research system in the UK, ensuring that all patients, including those with brain tumours, have access to cutting-edge clinical research and innovative, lifesaving treatments.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →